Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

ClinicalTrials.gov ID: NCT05194540

Public ClinicalTrials.gov record NCT05194540. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Single-arm, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Subjects With Moderate-to-severe Atopic Dermatitis

Study identification

NCT ID
NCT05194540
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
LEO Pharma
Industry
Enrollment
136 participants

Conditions and interventions

Interventions

  • Tralokinumab Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 12, 2022
Primary completion
Jun 5, 2023
Completion
Jun 20, 2023
Last update posted
Mar 10, 2025

2022 – 2023

United States locations

U.S. sites
29
U.S. states
16
U.S. cities
27
Facility City State ZIP Site status
LEO Pharma Investigator Birmingham Alabama 35205
LEO Pharma Investigator Birmingham Alabama 35209
LEO Pharma Investigator Fort Smith Arkansas 72916
LEO Pharma Investigator Fountain Valley California 92708
LEO Pharma Investigator Fremont California 94538
LEO Pharma Investigational Site Inglewood California 90301
LEO Pharma Investigator Los Angeles California 90025
LEO Pharma Investigator San Diego California 92103
LEO Pharma Investigator San Diego California 92130
LEO Pharma Investigator Santa Ana California 92701
LEO Pharma Investigator Centennial Colorado 80111
LEO Pharma Investigator Farmington Connecticut 06032
LEO Pharma Investigational Site Hialeah Florida 33012
LEO Pharma Investigator Sanford Florida 32771
LEO Pharma Investigator Libertyville Illinois 60048
LEO Pharma Investigator Overland Park Kansas 66210
LEO Pharma Investigator Bangor Maine 04401
LEO Pharma Investigator Detroit Michigan 48202
LEO Pharma Investigator Portsmouth New Hampshire 03801
LEO Pharma Investigator Cortland New York 13045
LEO Pharma Investigator Horseheads New York 14845
LEO Pharma Investigator Bexley Ohio 43209
LEO Pharma Investigator Toledo Ohio 43617
LEO Pharma Investigator Tulsa Oklahoma 74136
LEO Pharma Investigator Portland Oregon 97210
LEO Pharma Investigator Dallas Texas 75225
LEO Pharma Investigator Frisco Texas 75034
LEO Pharma Investigator San Antonio Texas 78218
LEO Pharma Investigator Webster Texas 77598

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05194540, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 10, 2025 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05194540 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →